Donor lymphocyte infusions (DLI) have been the mainstay of treatment for chronic myeloid leukemia (CML) relapsing after allogeneic stem cell transplantation (allo-SCT). Imatinib mesylate (IM) is also effective in these patients. However, advanced phase relapse (APRel) responds poorly with either treatment. To test the possibility that combinations of DLI and IM might be more effective, 37 patients with CML relapsing after allo-SCT between August 1994 and May 2004 were studied. Ten had molecular relapse (MRel), 14 hematological relapse (HRel) and 13 APRel. Thirteen received DLI, 9 IM and 11 DLI þ IM. Four patients received DLI þ IM but not concurrently. Thirty (81%) patients responded (actuarial survival and current leukemia-free survival of 80.676.7% and 69.177.7%). Of 30 patients, 26 are in molecular remission (MR), median follow-up of 1226 days (range 249-3257) since relapse. Ten of 11 patients (including four with APRel) treated with DLI þ IM achieved MR in 3 months and all are alive in MR. In contrast, only two of 22 treated with either modality (1/13 DLI and 1/9 IM) achieved MR at 3 months, 15 are alive, 11 in MR. Four patients receiving nonconcurrent DLI þ IM are also alive in MR. In conclusion, DLI appears to synergize with IM to induce rapid and durable MR.
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Leukemic relapse in patients with chronic myeloid leukemia (CML), undergoing allogeneic stem cell transplantation (allo-SCT), varies between 5 and 60% depending on disease status at transplant. 1 Since first reported in 1990, donor lymphocyte infusion (DLI) has been the mainstay of treatment for relapsing CML. 2, 3 DLI achieves durable responses in 60-70% of patients relapsing with chronic phase (CP) CML. [3] [4] [5] [6] However, durable remissions in patients relapsing into accelerated or blastic phase are less frequent. 5, 7, 8 Second transplant has also been used in patients not responding to DLI, but transplant-related toxicity is significant. 9, 10 Imatinib mesylate (IM) is a promising alternative for treating CML relapsing after SCT. [11] [12] [13] [14] [15] IM induces complete cytogenetic responses (CCR) and sometimes molecular remissions (MR), in patients failing DLI, without the risk of graft-versus-host disease (GVHD). 11, 13 Currently it is not clear whether IM, DLI or combinations of the two agents represent the optimum approach to treating CML relapsing after SCT.
Before the advent of IM, our patients with CML who relapsed after SCT received single or multiple DLI varying from 5 Â 10 6 to 5 Â 10 7 CD3 cells/kg. After the introduction of IM, relapsing patients unable to return to the transplant center or those with clinically significant GVHD were treated with IM alone, while those able to receive DLI received IM in addition to DLI. In this retrospective analysis we compared response to DLI, IM or a combination of the two. Combination treatment was associated with more rapid, durable and complete responses.
Patients and methods
In total, 101 patients with CML received allogeneic HLA identical sibling stem cell transplants at NIH between 1993 and 2004. They gave written informed consent for treatment in IRB-approved transplant protocols. In all, 88 received conditioning regimens containing total body irradiation and cyclophosphamide with a T-cell depleted SCT and cyclosporine as GVHD prophylaxis. A total of 13 received a reduced intensity regimen of Fludarabine 125 mg/m 2 and cyclophosphamide 60 mg/kg followed by a peripheral blood stem cell transplant and cyclosporine as GVHD prophylaxis. Thirty-nine patients relapsed. Two were excluded as unevaluable for this analysis because they died of progressing blastic phase CML within 30 days of receiving a DLI. To study possible synergy between DLI and IM, the 37 remaining patients were assigned to four categories (1) treatment with DLI alone, (2) treatment with IM alone, (3) concurrent treatment with DLI and IM and (4) treatment with DLI followed by IM, or IM followed by DLI.
Definitions
CP was distinguished from advanced phase (AP) (accelerated and blastic phase) using the International Bone Marrow Transplantation Registry (IBMTR) criteria. 16 Current leukemia-free survival (LFS) was defined as the survival without evidence of leukemia at the time of most recent assessment. 17 Molecular relapse (MRel) was defined as positive BCR-ABL mRNA transcript on two consecutive readings with a minimum interval of 2 weeks. Hematological relapse (HRel) was defined as a sustained or rising neutrophil leucocytosis with typical differential counts of CP CML. Advanced phase relapse (APRel) was defined as either X10% blasts in peripheral blood or marrow, or X20% blasts plus promyelocytes in peripheral blood or marrow or X20% basophils within 4 weeks prior to treatment intervention.
Treatment of relapse
Between 1993 and 2001 relapsing CML patients received DLI in incremental doses of 1, 5 and 10 Â 10 7 CD3 þ cells/ kg given every 3 months or sooner if the disease progressed. Patients with a recent history of acute or chronic GVHD received 0.5 Â 10 7 CD3 þ cells/kg as the first dose. After IM was available, patients received IM 400-600 mg/day depending on tolerance. If the patient was able to return to the transplant center and was not currently being treated for acute or chronic GVHD, incremental DLI was given as described above. Four patients with APRel also received low dose interferon (3 Â 10 6 units, 3 times weekly) or hydroxyurea (n ¼ 1) to control blood counts at the onset of relapse treatment.
Response assessment
Complete blood counts and metabolic profiles were performed weekly for 1 month and monthly thereafter. BCR-ABL transcripts were monitored every 2-3 months, or monthly if BCR-ABL transcripts were persistently positive. Bone marrow cytogenetics were assessed initially at HRel and every 3-6 months in the presence of progressive disease. Complete hematological remission (CHR) was defined as normalization of peripheral blood absolute and differential counts and disappearance of all signs and symptoms of CML. MR was defined as the absence of BCR-ABL transcripts by methods described below.
BCR-ABL measurements
BCR-ABL expression was monitored serially in patient leucocytes using reverse transcription and PCR. Until 2003, each sample was processed as described previously 18 using double-nested PCR to amplify BCR-ABL and a single round of PCR to amplify ABL housekeeper cDNA. Product bands were detected using eithidium bromide and agarose gel electrophoresis. After July 2003, real-time PCR was introduced: leucocyte RNA was purified using RNAeasy (Qiagen, MD, USA), and transcribed using random hexamer primers and the GeneAmp transcription kit (Applied Biosystems, Branchburg, NJ, USA). Duplicate samples of the resulting cDNA were amplified 50 cycles in a lightcycler (Roche, Mannheim, Germany) using the primers and fluorescently labeled Taqman probe described by Mensink et al. 19 To assess RNA integrity, the housekeeper gene G6PDH was measured using a commercial real-time PCR kit (Roche, Indianapolis, IN, USA). In all cases, serial 10-fold dilutions of RNA prepared from the BCR-ABL positive cell line K562 were used as a positive control and RNA from the BCR-ABL negative cell line HMy was used as a negative control to detect sample contamination. Both assays could detect b2a2 and b3a2 translocations, but not translocations involving the minor breakpoint cluster region.
For the purposes of this analysis, a sample was considered positive for BCR-ABL if a detectable band was noted in a double-nested assay, or if either of two duplicate samples generated a measurable crossing point in the real-time PCR assay. Samples were considered negative if no BCR-ABL band was detected and the housekeeper gene expression assay confirmed RNA integrity. The double-nested assay and real-time BCR-ABL assays were comparable in sensitivity. Each could detect BCR-ABL transcripts in K562 RNA diluted to 1 : 100 000-1 000 000 in control RNA.
Statistical analysis
The end points were calculated on January 15, 2005 (date of the last follow-up). Fisher's exact test, the w 2 test or Mann-Whitney test were employed to compare groups where appropriate. Outcome probabilities such as MR, CCR, CHR and survival were calculated using the KaplanMeier method. The log rank test was used to compare survival curves. All quoted P-values are two sided, and statistical significance was accepted at Po0.05.
Results

Characteristics and overall response
A total of 37 patients with CML relapsing after SCT were analyzed. Median time to relapse from SCT was 511 days (range 37-2228). In all, 10 patients had MRel, 14 HRel and 13 APRel. Thirty patients (81%) responded with an actuarial survival and current LFS of 80.676.7% and 69.177.7%, respectively ( Figure 1 ). Of the 30 patients, 26 were disease free at a median follow-up since relapse of 1226 days (range 249-3257). Actuarial survival for MRel, HRel and APRel was, respectively, 100, 100 and 43.3714.3% for survival, and 70714.5, 92.377.4 and 43.3714.3% for current LFS ( Figure 2) .
Seven of 13 patients with APRel died despite treatment with DLI (n ¼ 6) and Imitanib (n ¼ 1); all six patients who received DLI died before IM was available. Median time to death from relapsed disease was 179 days (range 126-741).
Comparisons of treatment approaches
Thirteen patients (two MRel, five HRel and six APRel) were treated with DLI alone, nine (five MRel, two HRel and two APRel) with IM alone and 11 (one MRel, six HRel and four APRel) with combined DLI þ IM. Four patients (two MRel, one HRel and one APRel) received nonconcurrent treatment with DLI and IM (interval between initiating the two treatments 46 months).
We compared the 33 patients receiving DLI, IM or concurrent DLI þ IM. Patient characteristics are shown in Table 1 . The distribution of APRel between the single or combination treatment groups was not statistically different (39, 27 and 33% in DLI, IM and DLI þ IM, respectively; P ¼ 0.52).
Molecular remission. Patients given DLI þ IM had rapid MR; 10/11 patients achieved an MR at 3 months. In contrast, patients treated with one modality had slower responses: only 2/22 (1/13 DLI and 1/9 IM group) achieving MR at 3 months (Po0.0001). (Table 2 ). Time to achieve MR was significantly shorter in DLI þ IM patients compared to single modality treatment (P ¼ 0.014, Table 3 ). All four patients with APRel given DLI þ IM had rapid MR. Two of these received additional low dose interferon to control blood counts at the onset of relapse treatment. In contrast, all six patients treated with DLI for APRel died (despite additional interferon in two), as did 1/2 APRel patients treated with IM, not eligible for DLI because of active GVHD.
Survival. Of the 11 patients treated with DLI þ IM, all are alive in MR (median survival 1722 days) compared with only 15/22 patients alive in single modality groups (7/13 DLI and 8/9 IM) and only 11 achieving MR. Detailed comparisons of treatment groups and outcome are described in Table 3 . Actuarial survival and current LFS of the three treatment groups are shown in Figure 3 .
Discontinuation of treatment. After documentation of persistent MR (BCR-ABL negative at least twice at a 3 month interval), IM was discontinued in 11 patients (DLI þ IM ¼ 7 and IM ¼ 4). All seven patients given DLI þ IM maintained MR (median 492 days, range 83-947) compared with only 1/4 in the IM group (one patient maintaining MR 393 days after stopping IM). In the three remaining patients, MR was re-established when IM treatment was resumed.
GVHD. After initiating treatment for relapse, grade I GVHD developed in eight patients (DLI ¼ 5/13, IM ¼ 1/9 and DLI þ IM ¼ 2/11). No patient developed grade X2 or extensive skin GVHD and there were no deaths related to treatment. Treatment was well tolerated, and only two patients given IM alone required dose reduction to 400 mg/ day for hematological toxicity; one failed to achieve MR. Nonconcurrent DLI and IM. Four patients (two MRel, one HRel and one APRel) were excluded from the comparative analysis because of long delays between the two treatment modalities. Three patients had multiple DLI (up to 10 8 CD3 þ cells/kg) over a 4-12 month period without response. Two patients (HRel and APRel) also had interferon for cytoreduction. All three promptly entered stable MR after IM was started. The fourth patient had received IM for more than a year with persistent molecular disease and achieved MR within 3 months of receiving DLI. All are currently alive in MR at 919, 1280, 1422 and 2397 days since relapse.
Discussion
Since the pioneering work of Kolb et al, 2 DLI has been considered the most effective means of treating CML relapsing after SCT. After DLI, molecular and HRel have up to an 80% chance of a prolonged durable MR. Patients relapsing into AP of CML fare worse, with salvage rates of 0-25%. 2, 3, 5, 7, 20 DLI has a mortality of between 3 and 10%, mainly from marrow aplasia or GVHD. 4, 7, 20 The availability of IM in the last 5 years, with its unique antileukemic properties and excellent toxicity profile, has stimulated many investigators to evaluate IM rather than using DLI to treat CML relapsing after SCT. Small case series 12, 13 and a recent multicenter study 11 showed that IM can achieve MR in 37-70% of patients. 11, 13 There are no published data on combinations of DLI and IM to treat relapses after allo-SCT. However, the cytoreductive ability of IM coupled with the established 'operational' cures of CML by DLI suggests a potential synergy between the two modalities.
At NIH, between 1993 and 2001 patients received DLI as the primary treatment for relapsed CML. After IM was available, IM was used alone for patients who could not return to the transplant center for DLI (usually because 
Table 2
Time to molecular remission they lived outside the United States), or for those who were receiving treatment for GVHD. When patients were able to receive DLI, we combined the two treatment approaches. Since the three groups included a similar proportion of MRel þ HRel vs APRel, it was possible to compare the outcomes of the three treatment modalities. We describe separately four patients treated by both approaches but with long delays between DLI and start of IM.
Our results confirm that IM is safe and well tolerated in combination with DLI in patients with CML who relapse after allo-SCT. Furthermore, we observed a beneficial effect of the DLI þ IM combination compared with the use of either agent alone: with the combination, patients achieved MR more rapidly, were able to stop IM without recurrence of molecular disease and had a superior diseasefree survival after treatment. The time to MR after DLI þ IM was shorter than reported after DLI alone 7 or IM alone 11, 13 (90, 7.7 and 11% for DLI þ IM, DLI and IM, respectively, at 3 months in our study). Studies have shown rapidity of MR after transplant to be an important factor for remaining in remission. 21, 22 The importance of DLI in the response we observed is highlighted by the fact that the time to MR appears faster than reported in patients given IM in the absence of prior transplantation 23 (Table 2 ). In our study, 90% of patients achieved MR at 3 months when combination treatment was given, and all patients in the combination group are currently BCR-ABL negative at median time of 1016 days (range 249 to 1457) since relapse. Furthermore, patients receiving DLI þ IM required less total doses of IM and fewer DLI to achieve more stable MR (Table 3) . CML patient relapsing in AP remains a challenging problem. 12, 13, 24 The combination of DLI þ IM also appeared to be more effective than single treatments in achieving MR in patients with APRel. With a combination of DLI þ IM in APRel all four patients achieved MR and are currently disease free after 249-1247 days follow-up. Results appear to be superior to reported results with DLI 5, 7, 8, 25 or IM 11 alone, but we caution that our data were obtained retrospectively and concern relatively small subsets of patients. Further prospective studies are required to validate a benefit from IM þ DLI combinations.
While there are cases of GVHD (grade X2) reported in patients treated with IM after transplantation, 12 most studies found that IM is safe in the post transplant setting and does not increase the risk of GVHD. 11, 13, 14, 24, [26] [27] [28] Only two patients receiving the combination of DLI þ IM developed GVHD, raising the question (in view of the reported immunosuppressive effect of the IM 29, 30 ) of whether the DLI added any GVL effect to the responses Table 3 Comparisons of treatment approaches observed. We believe a GVL effect was, nevertheless, achieved since the mean DLI dose of 1.7 Â 10 7 /kg CD3 cells (Table 3) given to our patients in this group was found by Mackinnon et al 31 to induce remission without GVHD in 7/8 patients.
As we were interested in studying the effect of the concurrent use of DLI and IM, we analyzed separately four patients who received DLI þ IM, where the prolonged interval between starting the two treatments made it difficult to attribute response to the combination. Nevertheless, all four patients promptly achieved MR after delayed addition of either IM or DLI, suggesting again that the combination treatment was important in the rapid achievement of stable MR.
An unresolved issue is when or whether to stop IM in patients in MR. We stopped IM in 11 patients (seven in DLI þ IM and four in IM group). Whereas the DLI þ IM recipients achieved stable MR, the IM alone patients relapsed again, and are now maintained on IM. These results encourage us to expect that combination treatment should permit withdrawal of IM after stable MR has been achieved.
What is the basis for this apparent synergy of DLI and IM? There are abundant data that IM can reduce disease bulk in CML but little evidence that leukemic progenitors are permanently eliminated, since disease recurrence typically follows withdrawal of IM. In contrast, DLI is believed to exert an immune-mediated GVL effect, which can often permanently eliminate residual disease. However, while DLI achieves durable MR, the process is most effective at a molecular level of persisting disease, and to be effective it may take many months and require escalating doses of DLI, conferring a higher risk of GVHD. The combination of DLI and IM is therefore logical -IM may reduce disease burden readily to levels below molecular detection, but alone it is incapable of preventing recurrence. A single DLI given in the context of IM may be more effective, because the residual disease burden is very low and the more efficient GVL effect created durably suppresses residual CML progenitors, allowing IM to be safely withdrawn. In our data, synergy of the two modalities is suggested by the shorter duration of IM and the use of single DLI to achieve rapid responses in all stages of CML relapse.
We must, nevertheless, be cautious in drawing definitive conclusions from this retrospective, nonrandomized, observational study. Our patients were nonrandomly allocated treatment according to availability of IM, or constraints in their ability to receive DLI. Nevertheless, the data strongly suggest that DLI and IM are best used in combination, to achieve durable MR in CML relapsing after transplant. We hope these findings will help shape future prospective studies evaluating DLI and IM as an effective treatment for all stages of relapse of CML after SCT.
